LAG-3 Targeted Drug Development Summit

The LAG-3 Targeted Drug Development Summit is dedicated to the progressing of the next clinically validated checkpoint inhibitor and propelling it to clinical use as LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors.

The LAG-3 Targeted Drug Development Summit covers topics such as:

• Improving combination therapy regimens
• The progress that has been made and challenges faced in bispecific antibody based approaches
• Biomarkers to understand the interplay between PD-1 and LAG-3
• Underpinning biology of LAG-3 as a cancer target

The LAG-3 Targeted Drug Development Summit brings together senior attendees involved or interested in LAG-3 Targeted Drug Development.